Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase 2 studyClaudia Cardone, Antonio Avallone, Lucrezia Silvestro et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase 2 studyClaudia Cardone, Antonio Avallone, Alfonso De Stefano et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0